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About the journal 
4
 Introduction 
 Breast cancer is one of the  most deadliest cancer types in women.
 Conventional chemotherapy and radiotherapy .
 The overexpression of the epidermal growth factor receptor (EGFR) 
 Overexpression 82-90%
 Including increased cancer cell , proliferation and inhibited apoptosis.
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 Introduction 
 Cetuximab (CET) is a monoclonal antibody treatment that has been used to 
target EGFR signaling in cancer cells .
 Anti-cancer effects in EGFR-overexpressing tumor cells in vitro and in vivo
 Inhibit or reduce the growth of cancer cells









 Doxorubicin (DOX) is one of the most powerful chemotherapy drugs
 Activates cell apoptosis
 kill cancer cells at every point in their life cycle
 CET and DOX is often hampered by their side effects, including 
dose-dependent cardio-toxicity.
 Their lack of specificity towards cancer cells, which can result in systemic 
cytotoxicity. 8
 Introduction
 Various novel cancer therapeutic strategies have been proposed to improve 
the local targeting of anti-cancer treatments to the tumor cells .
 Therapies that are responsive to external stimuli such as light, magnetic 
field, ultrasound, and radio-frequency.
 Magnetic nanoparticles (MNPs) have been used for targeted drug delivery in 
combination with external exposure to a magnetic field that enables the local 
delivery of therapeutic and diagnostic agents.
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 Introduction 
 Iron oxide (Fe3O4) MNPs have also been used as a delivery system for 
chemotherapeutics, gene therapeutics, and photo- thermal therapeutics .
 Biocompatibility, and ease of size control.
 Generate heat when exposed to near-infrared (NIR) laser irradiation.
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 Introduction 
 Thermo-sensitive liposomes (TSLs), release the encapsulated drug when 
heated to fever temperatures (∼40–42°C)
 Biocompatibility, biodegradability, and loading capacity.
 Iron oxide nanoparticles exhibit excellent photo-thermal treatment efficacy 
when excited by NIR laser irradiation .
 Loading of these iron oxide nanoparticles into TSLs improved NIR-laser-
triggered drug release.
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Materials and methods 
Synthesis of Citric Acid-Coated Fe3O4-MNPs (CMNPs)
 Dissolving 0.875 g FeCl2 and 2.375 g FeCl3 (Fe2+: Fe3+ = 1:2) 
 In 40 mL of double-distilled water (DDI water) 
 100 rpm for 15 min at 80°C 
 The stirring speed was increased to 1000 rpm and 
 5 mL NH4OH …30 min
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Coat MNPs with citric acid 
• The temperature of the solution was increased to 95°C 
• Citric acid was added drop by drop 
• The reaction was proceed further for 90 min. 
• Cooling at room temperature 
• Diluted twice with DDI water and subjected to magnetic separation for 10 min 
• The supernatant containing CMNPs 
• Washed with DDI water in a 10 kDa molecular weight cut-off (MWCO) hollow 
fiber module 
• Remove excess citric acid and NH4OH 14
Preparation of CMNP-TSLs
 30mg DPPC, 6 mg DSPE-mPEG-2000 and 4mg MPPC
 Dissolved in a chloroform/methanol solution (2:1 V/V). 
 The organic solvent was removed using a rotary evaporator 
 39°C with a water bath for 2 h. 
 Rehydrated with an ammonium sulfate 
 sonicated for 15 min. 
 the liposomes were extruded 
 using double-stacked polycarbonate membranes filter
 The un-encapsulated CMNPs were removed by centrifugation 
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Preparation of DOX-Loaded CMNP-TSLs (DOX-CMNP-
TSLs)
 An ammonium sulfate plus CMNP-TSLs suspension 
 Ion exchange mechanism
 Ammonium ion is exchanged with the drug
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Preparation of CET-Coated DOX-CMNP-TSLs (CET-DOX-
CMNP-TSLs)
 0.6mg DSPE- mPEG-COOH was added to NHS and EDC (molar ratio 1:1) 
 pH 7.4 for 30 min
 2.0 mg of CET was added at 4°C and incubated for 12 h
 Obtain CET-DSPE-mPEG-COOH 
 The DOX-CMNP-TSLs solution and CET-DSPE-mPEG-COOH solution were 
mixed and shaken at 4°C in the dark for 5 h to obtain CET- DOX-CMNP-TSLs 
 The unconjugated CET was removed by chromatography
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Determination of Loading Efficiency of DOX into CMNP-TSLs
 The quantity of CMNPs and DOX in the TSLs was determined by 
spectrophotometry
 Using aqua regia to dissolve the sample 
 Using DDI water to dilute the sample. 
 The sample solution was added to sulfosalicylic acid solution. 
 1.0 mL of an NH3-NH4Cl buffer solution was added
 total volume was increased to 5 mL with the addition of DDI water 
 gentle shaking and measurement of absorbance of the solution at 380–460 nm 
using a UV– VIS spectrophotometer 
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• For the content of DOX, the measurement was conducted after denaturing the 
emulsion with absolute alcohol 
• the absorbance value at 480 nm
• The CMNPs and DOX concentrations were determined using a standard 
curve 
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Determination of Conjugation Efficiency of CET Onto TSLs
 BCA protein assay (is used for quantitation of total protein in a sample)
 50 parts of the BCA Reagent A with 1 part of the BCA Reagent B (50:1, 
Reagent A:B) 
 20 μL sample and 200 μL working agent at 37°C for 30 min
 absorbances were determined at the wavelength of 570 nm 
 Unconjugated CET was removed by chromatography 
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Characterization of CMNPs, TSLs and CET-DOX- CMNP-TSLs
 The particle size and zeta potential dynamic light scattering (DLS) 
 Surface morphology of the nanoparticles          TEM
 the magnetic properties of the CMNPs vibrating sample magnetometer
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Measurement of Photo-Thermal Sensitivity of CMNPs in CET-
DOX-CMNP-TSLs
 Aqueous suspensions of CET-DOX-CMNP-TSLs were prepared 
 1 mL/sample was loaded into a 96-well microplate. 
 Irradiated by NIR at λmax 808 nm with a laser at 2 W/cm2 for 5 min 
 Imaged with a thermal imaging camera every 1 min. 
 Different concentrations of 20, 50, 100, 200, and 500μg/ mL of CMNP-TSLs. 
 The temperature of the sample solution was measured every 1 minute using a 
thermocouple 
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Determination of in vitro NIR-Triggered DOX Release
• Release of DOX from the various formulations 
(DOX-TSLs, DOX-CMNP-TSLs, and CET- DOX-CMNP-TSLs) 
• pH 7.4, 6.8, and 5.5
• The influence of pH and NIR irradiation on drug release
• DOX-CMNP-TSLs and CET-DOX-CMNP-TSL
• Treated with NIR (λmax 808 nm, 2 W/cm−2 t=5min
• The same samples without NIR treatment
• UV-Vis spectrophotometer
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Assessment of Cellular Uptake of TSLs, CET-TSLs into Breast 
Cancer Cells
• SKBR-3 (over expressed EGFR) and MCF-7 (low expressed EGFR) 
• Studied by flow cytometry 
• Fluorescence microscopy 
• Both cell lines were seeded in 6-well plates cultured for 24 h
• Culture medium was discarded 
• Cells were cleaned 3 times with PBS
• Cells were incubated with 2 mL of serum-free medium  
• Containing fluorescent TSLs and CET-TSLs for 2h 24
Assessment of Cellular Uptake of TSLs, CET-TSLs into 
Breast Cancer Cells
• Cell culture medium was discarded 
• Cells were cleaned three times with cold PBS 
• Fluorescence microscope 
• Quantification of uptake efficiency by a flow cytometer
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Determination of in vitro Cytotoxicity of CET-CMNP-TSLs and 
CET-DOX-CMNP-TSLs
 The cells were cultured in RPMI 1640 medium 
 10% fetal bovine serum (FBS) 
 1% penicillin/streptomycin
 The cytotoxicity of CET-CMNP-TSLs and CET-DOX- CMNP-TSLs
was determined by MTT assays 
 Assessment of in vivo Photo-Thermal Treatment Efficacy
• Tumor- bearing BALB/C mice 
• 1×105 SKBR-3 cells 
• Injected subcutaneously into the armpit region 
• Two weeks after the cell injection 
• All mice (n=15) were divided into 3 groups 
• 200 μL of normal saline, CMNP- TSLs and CET-CMNP-TSLs 
• The tumors were irradiated with a NIR laser (after 24h) 27
 Assessment of Biosafety of CMNP in Formulations – Hemolysis 
Assay 
• CMNPs, CMNP-TSLs, CET-CMNP-TSLs and CET-CMNP-TSLs+NIR
• Blood samples from healthy rabbits 
• Centrifugation at 1000 rpm for 10 min 
• washed three times with normal saline 
• Positive and negative controls, 2% RBCs suspensions were made with 
deionized water and normal saline separately
• All samples were diluted with normal saline at a concentration of CMNP at 
10, 20, 30, 40 and 50 μg/mL 
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• Incubated with 2% of RBCs at 37°C for 3 h. 
• CET-CMNP-TSLs group was irradiated with NIR radiation at 2 W/cm2 for 5 
min 
• All treated samples were centrifuged at 1000 rpm for 10 min 
• The supernatant from all samples was collected 
• The absorbance was measured at 570 nm 
29
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The magnetization curve of CMNPs as measured by 
VSM 
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Photo-Thermal Sensitivity Effect of CMNP-TSLs
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In vitro NIR-Triggered Release of DOX 
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Breast Cancer Cell Uptake of TSLs and CET-TSLs and Cell Viability 
Following Treatment with CET-CMNP-TSLs, CET-DOX-CMNP-TSLs
36
37
Photo-Thermal Impact of NIR Laser Irradiation Plus CET-





• In this study, we designed CET-DOX-CMNP-TSLs when integrated with 
NIR laser irradiation therapy, enhanced antitumor efficacy. 
• Effective treatments for many forms of cancer are still lacking.
• Smaller nanoparticle size (<200nm) enhances accumulation of the 
nanoparticles at tumor sites , In our study  it was 117±3nm
• DOX and CMNPs loading into the TSLs were enabled by a citric acid coating 
of MNPs which provides an electrostatic environment
• Similar work was reported by others in which the loading of DOX onto 
PEGylated-cationic iron oxide was stabilized by citric acid.
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• the release of DOX from NIR irradiated samples in acidic media at pH 6.8 
and 5.5 was comparatively higher than at pH 7.4 and non-irradiated samples
• The pH in the tumor microenvironment is weakly acidic , the released DOX 
in tumors is more than in normal tissues 
• Cancer cells express various types of receptors, with which a specific 
antibody can bind to facilitate selective antibody-targeted therapeutic effects; 
these include folate, integrin, and EGFR
• various researchers have demonstrated the selective internalization of 
monoclonal antibody-modified nanoparticles in comparison to non-modified 
nanoparticles
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• Studies by others and us have demonstrated the selective binding of CET with 
EGFR expressed on breast cancer cells
• the uptake of CET-TSLs was greater in comparison with the uptake of TSLs in 
SKBR-3 cell lines than in MCF-7 cell; similar results have been reported by 
others
• combination therapies have often shown better, efficacy in comparison to 
monotherapies
• combination of chemotherapeutic and photo-thermal therapy should be 
considered as a promising strategy to enhance the anti-cancer impact of 
chemotherapeutics
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• Iron-based nanoparticles, have been explored as a possible nanocarrier system 
for various anti-cancer drugs
• To exploit the thermal and magnetic properties of iron oxide, we prepared 
CMNP and DOX-loaded TSLs that were coated with CET to target EGFR-
expressing breast cancer cells
• Our results showed that breast cancer cell viability significantly declined 
when NIR radiation was added to cells treated with the chemotherapeutic 
nanocarrier.
• Free DOX was also able to decrease breast cancer cell viability to a similar 
but much higher doses were required 
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• NIR laser irradiation could be combined with chemotherapeutic nanocarriers
to reduce the dose of a chemotherapeutic drug required for treatment efficacy
• the tumor surface temperature found during NIR laser irradiated mice treated 
with CET-CMNP-TSLs or CMNP-TSLs, was substantially greater in 
comparison to the mice treated with normal saline 
• hemolysis assays showed that these nanocarriers are biocompatible and safe
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 Conclusion 
• we have developed a novel and selective chemotherapeutic nanocarrier
system
• facilitates drug delivery to EGFR-expressing breast cancer cells enhancing the 
impact of photo-thermal therapy
• These CET-DOX-CMNP-TSLs reduced breast cancer cell viability and 
increased tumor temperature when combined with NIR laser irradiation
• iron oxide MNPs is promising nanomaterial for photothermal tumor therapy
• iron oxide could be more easily degraded and metabolized in the body
• iron oxide MNPs encapsulating by TSLcould achieve NIR-triggered drug 
release behavior which will demonstrate desirable photothermal therapeutic 
efficiency
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